Mode
Text Size
Log in / Sign up
Phase 3 Completed N=250 Randomized Treatment

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

Source: ClinicalTrials.gov NCT04472611 ↗
Enrolled (actual)
250
Serious AEs
3.2%
Results posted
Apr 2023
Primary outcomePrimary: Number of Participants With COVID 19 Severity — 5; 4; 2; 0 Participants
◆ Published Evidence
Emerging
13citations · ~4 / year
Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial.
BMJ open · 2023 · Open access · Likely link

Summary

This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2

Linked Publications (2)

  • Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial.
    BMJ open · 2023 · 13 citations · Open access · Likely link
  • Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial.
    Contemporary clinical trials · 2021 · 6 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With COVID 19 Severity
5; 4; 2; 0; 4; 1

Eligibility Criteria

Inclusion Criteria 1.18 years or older and confirmed SARS-CoV-2 infection by RT-PCR 2. Patient is admitted to the floor (non-ICU) within 48 hours of hospital admission 3. The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided witnessed (by 2 independent members of the health care team) oral informed consent, or a photograph of the signed informed consent approved by the Institutional Review Board (IRB)

Exclusion Criteria

  • Known pregnancy or nursing mothers
  • Known allergy to statins or colchicine
  • Patient is on chronic colchicine or oral corticosteroid treatment
  • Acute liver disease defined by elevated transaminases (AST/ALT > 3x ULN)
  • Severe chronic kidney disease defined as glomerular filtration rate (GFR) 500ms narrow QRS 550ms for wide QRS>120)
  • Presents with severe disease on admission (WHO ordinal scale of clinical improvement scores 5-8)
  • Rhabdomyolysis or CPK > 5x ULN
  • Thrombocytopenia defined as platelet count < 50,000 / mm3
  • Leukopenia defined as white blood cell count < 3000 ml
  • Severe anemia defined as Hemoglobin value <8 g/100ml
  • Participation in any other clinical trial of an experimental treatment for COVID-19
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04472611) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search